参考文献：
1. Mikuls Ted R,Johnson Sindhu R,Fraenkel Liana,Arasaratnam Reuben J,Baden Lindsey R,Bermas Bonnie L,Chatham Winn,Cohen Stanley,Costenbader Karen,Gravallese Ellen M,Kalil Andre C,Weinblatt Michael E,Winthrop Kevin,Mudano Amy S,Turner Amy,Saag Kenneth G. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.[J]. Arthritis & rheumatology (Hoboken, N.J.),2020.DOI 10.1002/art.41596
2. Gianfrancesco M, Hyrich KL, Yazdany J, et alCOVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al Annals of the Rheumatic Diseases 2022;81:e191.
3. Popescu I, Snyder M E, Iasella C J, et al. CD4+ T cell lymphopenia and dysfunction in severe COVID-19 disease is autocrine TNF-α/TNFRI-dependent[J]. bioRxiv, 2021.
